Rheocarna treatment for non-dialysis patients

Rheocarna 用于非透析患者

阅读:2

Abstract

INTRODUCTION: Rheocarna has attracted attention as an alternative therapy for severe chronic limb-threatening ischemia, and there have been reports of its usefulness. However, most of these reports have been on dialysis patients, and there are few reports on the treatment conditions and efficacy in non-dialysis patients. METHODS: Four non-dialysis patients who received Rheocarna were studied to determine the conditions under which it was administered and its effectiveness. RESULTS: The ulcer healed completely, but two patients required skin grafting. The treatment time and blood flow rate were 90-120 min and 50-80 mL/min, respectively. The processed volume was about 1.0 times the circulating blood volume, and the removal rate of low-density lipoprotein and fibrinogen was about 10%-15%. CONCLUSION: The ulcers healed despite the removal rate of low-density lipoprotein and fibrinogen being small. To our knowledge, this is the first report on the treatment conditions and effectiveness of Rheocarna in non-dialysis patients.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。